Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: Validation of a simplified method suitable for multi-center clinical studies

• Published in: Leukemia research Vol. 34; no. 6; pp. 809 - 815
• Main Authors: Hayes, Gregory M, Busch, Robert, Voogt, Jason, Siah, Iche M, Gee, Tracy A, Hellerstein, Marc K, Chiorazzi, Nicholas, Rai, Kanti R, Murphy, Elizabeth J
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2010
• Subjects: Adult; Aged; B-Lymphocytes - pathology; Blood Specimen Collection - methods; Blood Specimen Collection - standards; Bone Marrow Cells - pathology; Cell isolation; Cell Proliferation; Cell Separation - methods; Clinical Trials as Topic - methods; CLL; Cytodiagnosis - methods; Deuterium Oxide - chemistry; DNA - analysis; Efficiency; Female; Flow Cytometry - methods; Hematology, Oncology and Palliative Medicine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - blood; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Male; Middle Aged; Multicenter Studies as Topic - methods; Cell proliferation; Cell isolation; CLL
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2009.09.032

Abstract Background Heavy water (2 H2 O) labelling of DNA enables the measurement of low-level cell proliferation in vivo, using gas chromatography/pyrolysis isotope ratio mass spectrometry (GC/P/IRMS), but the methodology has been too complex for widespread use. Here, we report a simplified method for measuring proliferation of malignant B cells in patients with chronic lymphocytic leukemia (CLL). Design and methods Patients were labelled with2 H2 O for 6 weeks; blood samples were obtained at 0, 3, and 6 weeks during2 H2 O labelling and 9, 12, and 16 weeks thereafter. Bone marrow was sampled at week 6. Phlebotomy was performed at multiple, non-research clinical sites. CLL cells were isolated in a central laboratory, using a novel RosetteSep™-based method; DNA labelling was analyzed by GC/P/IRMS. Results In 26 of 29 patients, CLL cell isolation resulted in ≥95% purity for malignant CD5+ B cells; in one patient, malignant cells expressed marginal levels of CD5, and in two others, further sorting of CD5hi malignant cells was required. Cell yields correlated with white blood cell counts and exceeded GC/P/IRMS requirements (≈107 cells) >98% of the time; high-quality DNA labelling data were obtained. RosetteSep isolation achieved adequate CLL cell purity from bone marrow in only 64% of samples, but greatly reduced subsequent sort time for impure samples. Conclusion This method enables clinical studies of CLL cell proliferation outside of research settings, using a shorter2 H2 O intake protocol, a minimal sampling protocol, and centralised sample processing. The CLL cell isolation protocol may also prove useful in other applications. (clinicaltrials.gov identifier: NCT00481858 ).